Stronger recovery is possible for your patients. ANEUVO ExaStim® Therapy expands options for people with spinal cord injuries (SCI) by helping to improve hand sensation and strength.
Spinal cord injury (SCI) is a life-altering condition that results in partial or complete loss of motor and sensory function below the level of injury. The World Health Organization estimates that between 250,000 and 500,000 new cases occur each year.1 With therapy, support, and assistive devices, most people with SCI are able to improve their strength and mobility, and adapt to the effects of their injuries—but they may still struggle with daily tasks like showering, dressing, and preparing meals. ExaStim was developed to help people with SCI regain lost movement, strength, and functionality, so they can enjoy greater independence.
The ExaStim Transcutaneous Spinal Stimulation (TSS) system is a non-invasive multi-electrode system that helps to improve and optimize treatment for patients with spinal cord injuries. As a non-surgical neurostimulation device, it provides transcutaneous spinal stimulation without the need for device implantation.
ExaStim has been evaluated for safety and effectiveness and has FDA clearance. Clinical studies have shown promising results for people living with spinal cord injuries.
Transcutaneous spinal stimulation is a non-invasive medical therapy that has been shown to improve or restore motor function in patients who are experiencing limited function or paralysis due to a chronic spinal cord injury.2 It works by modulating the spinal cord circuitries. To do this, electrodes are externally placed on a patient’s back, and electrical stimulation is delivered via the electrodes by a portable pulse generator (PPG). This system is used to facilitate motor function recovery.
Technology
ANEUVO is focused on treating disabling injuries and conditions that have not been curable through traditional pharmaceutical approaches. Our innovative ExaStim Stimulation System has been designated as a Breakthrough Device by the U.S. Food and Drug Administration (FDA) and has received FDA clearance and CE Mark approval in Europe. When used in combination with rehabilitation, ExaStim helps patients to improve hand sensation and strength.
Dexterity
What could improved hand dexterity mean for your patients?
Results from ANEUVO clinical studies show 85% of patients experienced an improvement in dexterity in one or both hands that was sustained even 4 weeks after cessation of treatment.* Building dexterity can make it easier for patients to manage daily tasks like writing, dressing and housekeeping—leading to greater independence.
*Results from the ASPIRE Study. According to performance on 9-Hole Peg Test.
Data based on analysis of Modified Intent-to-Treat (MITT), treatment as administered population.
The Company
U.S. market entry furthers global mission for accessible clinical and at-home non-invasive neuromodulation therapy Los Angeles, CA, April 16, 2026 (GLOBE NEWSWIRE) -- ANEUVO, a...
Read more
U.S. market entry furthers global mission for accessible clinical and at-home non-invasive neuromodulation therapy Los Angeles, CA, April 16, 2026 (GLOBE NEWSWIRE) -- ANEUVO, a...
Read more
EASTHAMPTON, MA (WGGB/WSHM) -- Nearly a decade after a training ride crash left him with a spinal cord injury, an Easthampton man is regaining function...
Read more
Proceeds to support manufacturing growth, regulatory advancement, and disciplined commercialization expansion Los Angeles, CA, March 05, 2026 (GLOBE NEWSWIRE) -- ANEUVO, a medical technology company...
Read more
Honor highlights international startup advancing non-invasive rehabilitation technology for people living with chronic spinal cord injury Los Angeles, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) --...
Read more
The first MDR-Approved Non-Invasive Spinal Stimulation System in Europe Los Angeles, CA, Sept. 16, 2025 (GLOBE NEWSWIRE) -- ANEUVO today announced its participation in two...
Read more
Key Milestone Signals Readiness for European Market Entry and Commitment to Quality Los Angeles, CA, April 09, 2025 (GLOBE NEWSWIRE) -- ANEUVO, a pioneer in...
Read more
This new phase of clinical research will test the safety and feasibility of ANEUVO’s non-invasive therapy for future use by individuals living with chronic spinal...
Read more[1] Christopher & Dana Reeve Foundation. (n.d.). Statistics about paralysis. Retrieved from https://www.christopherreeve.org/todays-care/paralysis-help-overview/stats-about-paralysis
[2] Taylor C, McHugh C, Mockler D, Minogue C, Reilly RB, Fleming N. (2021) Transcutaneous spinal cord stimulation and motor responses in individuals with spinal cord injury: A methodological review. PLoS One. 2021 Nov 18;16(11):e0260166.
